Most peri-operative harm from antithrombotic drugs comes from two opposite errors: stopping a drug that should have continued, and restarting one too early. The American College of Chest Physicians (ACCP) 2022 guideline covers vitamin K antagonists, heparin bridging, direct oral anticoagulants (DOACs) and antiplatelet drugs in patients having elective procedures [1], and recent reviews in JAMA summarise a standardised approach [2, 11]. Every plan starts from the same facts:
- The bleeding risk of the procedure: minimal (for example minor dental or skin procedures), low to moderate (for example cholecystectomy or inguinal hernia repair) or high [2].
- The thrombotic risk of the patient: the indication, recent events, valve type and, in atrial fibrillation, the CHA2DS2-VASc score.
- The drug, dose and time of the last dose, with creatinine clearance estimated by Cockcroft-Gault.
- Whether spinal, epidural or deep nerve block anaesthesia is planned.
- The urgency: in an emergency the question changes from interruption to reversal.